Reviewing Dicerna Pharmaceuticals Inc. (DRNA)’s and Proteostasis Therapeutics Inc. (NASDAQ:PTI)’s results

Since Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) and Proteostasis Therapeutics Inc. (NASDAQ:PTI) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership of both companies.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dicerna Pharmaceuticals Inc. 19 0.00 46.66M -1.70 0.00
Proteostasis Therapeutics Inc. 1 0.00 35.73M -1.58 0.00

Table 1 highlights Dicerna Pharmaceuticals Inc. and Proteostasis Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us the return on equity, return on assets and net margins of both companies.

Net Margins Return on Equity Return on Assets
Dicerna Pharmaceuticals Inc. 243,528,183.72% -66.1% -37.2%
Proteostasis Therapeutics Inc. 3,007,069,516.92% -84% -64.7%

Volatility and Risk

Dicerna Pharmaceuticals Inc. has a beta of 2.14 and its 114.00% more volatile than Standard & Poor’s 500. Proteostasis Therapeutics Inc.’s -0.71 beta is the reason why it is 171.00% less volatile than Standard & Poor’s 500.

Liquidity

Dicerna Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 5 and 5 respectively. The Current Ratio and Quick Ratio of its competitor Proteostasis Therapeutics Inc. are 11.3 and 11.3 respectively. Proteostasis Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Dicerna Pharmaceuticals Inc.

Analyst Recommendations

Dicerna Pharmaceuticals Inc. and Proteostasis Therapeutics Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Dicerna Pharmaceuticals Inc. 0 0 4 3.00
Proteostasis Therapeutics Inc. 0 0 0 0.00

Dicerna Pharmaceuticals Inc.’s upside potential is 15.20% at a $31 consensus price target.

Institutional & Insider Ownership

Dicerna Pharmaceuticals Inc. and Proteostasis Therapeutics Inc. has shares owned by institutional investors as follows: 90% and 60.5%. Insiders owned 8.38% of Dicerna Pharmaceuticals Inc. shares. Comparatively, insiders own roughly 0.3% of Proteostasis Therapeutics Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Dicerna Pharmaceuticals Inc. -10.03% -12.68% 8.52% 35.62% 9.57% 27.5%
Proteostasis Therapeutics Inc. -9.53% -15.14% -23.06% -72.83% -64.36% -74.59%

For the past year Dicerna Pharmaceuticals Inc. has 27.5% stronger performance while Proteostasis Therapeutics Inc. has -74.59% weaker performance.

Summary

On 6 of the 10 factors Dicerna Pharmaceuticals Inc. beats Proteostasis Therapeutics Inc.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. The company is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response (UPR) modulators that are in preclinical development. It has collaboration with Astellas Pharma, Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.